Business
Vor Appoints CFO Nathan Jorgensen
Vor Appoints CFO Nathan Jorgensen.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n RNS Number : 8399N\n PureTech Health PLC\n 26 May 2020\n \n \n \n \n 26 May 2020 \n \n \n PureTech Health plc\n \n \n \n PureTech Founded Entity Vor Biopharma Appoints Nathan Jorgensen, PhD, as Chief Financial Officer \n \n \n \n PureTech Health plc\n \n (LSE: PRTC) (\"PureTech\"\n or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, \n today announced that its Founded Entity Vor Biopharma has appointed Nathan Jorgensen, PhD, as Chief Financial Officer.\n \n \n \n \n \n Dr Jorgensen has over a decade of diverse experience in the financial industry focused on healthcare and biopharma at the Qatar Investment Authority (QIA), Calamos Investments and Stifel Nicolaus, as well as scientific doctoral and post-doctoral training. \n At QIA, the sovereign wealth fund of the State of Qatar, Dr Jorgensen spearheaded biotechnology and pharmaceutical investment efforts, which included opportunities in public, private, and specialty investments. Prior to joining QIA, he led investments in therapeutics at Calamos, a growth-focused public equity investment firm with $25 billion of assets under management. Before joining Calamos, Dr Jorgensen covered mid- and large-cap biotech companies at the investment bank Stifel Nicolaus. \n \n \n \n \n \n Prior to working on Wall Street, Dr Jorgensen investigated the pathobiology of Parkinson's disease at the Columbia University Medical Center as a post-doctoral scientist. \n \n \n \n \n \n The full text of the announcement from Vor Biopharma is as follows:\n \n \n \n Vor Biopharma Adds to Leadership Team with Appointment of Chief Financial Officer\n \n \n \n \n \n CAMBRIDGE, Mass., - May 26, 2020 - \n \n Vor Biopharma\n \n , an oncology company pioneering engineered haematopoietic stem cells (eHSCs) for the treatment of cancer, today announced the appointment of Nathan Jorgensen, PhD, as Chief Financial Officer. Dr Jorgensen has over a decade of diverse experience in the financial industry focused on healthcare and biopharma at the Qatar Investment Authority (QIA), Calamos Investments and Stifel Nicolaus, as well as scientific doctoral and post-doctoral training. \n \n \n \n \n \n \"Nathan is a rare combination of financial ...